Home › Malattia di Crohn › Texas › Tyler
Studi clinici su Malattia di Crohn a Tyler, TX
16 studi su Malattia di Crohn cercano partecipanti presso sedi a Tyler e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
In reclutamentoFase 3
- Tyler Research Institute ( Site 0294), Tyler
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
In reclutamentoFase 3
- Tyler Research Institute ( Site 5001), Tyler
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
In reclutamentoFase 2
- Tyler Research Institute /ID# 265545, Tyler
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
In reclutamentoFase 3
- The University of Texas Health Science Center at Tyler, Tyler
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
In reclutamentoFase 2/3
- Tyler Research Institute, LLC, Tyler
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
In reclutamentoFase 2
- Tyler Research Institute, LLC, Tyler
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
In reclutamentoFase 3
- Tyler Research Institute, Tyler
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
In reclutamentoFase 3
- Tyler Research Institute, LLC-Site Number: 8400095, Tyler
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
In reclutamentoFase 3
- Tyler Research Institute LLC-Site Number: 8400095, Tyler
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
In reclutamentoFase 2
- Tyler Research Institute, LLC, Tyler
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
In reclutamentoFase 4
- Tyler Research Institute, LLC, Tyler
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
In reclutamentoFase 3
- Tyler Research Institute, LLC, Tyler
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
In reclutamentoFase 3
- Tyler Research Institute, LLC, Tyler
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
In reclutamentoFase 2
- Tyler Research Institute, LLC, Tyler
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
In reclutamentoFase 2
- Tyler Research Institute, LLC, Tyler
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
In reclutamentoFase 2
- Mirador Therapeutics Selected Site, Tyler
Studi su Malattia di Crohn in altre città
- New York City, NY35 studi
- Cleveland, OH19 studi
- St. Louis, MO19 studi
- Boston, MA19 studi
- Miami, FL19 studi
- Orlando, FL17 studi
- Houston, TX17 studi
- Atlanta, GA17 studi
- San Diego, CA15 studi
- San Antonio, TX15 studi
- Los Angeles, CA15 studi
- Philadelphia, PA13 studi
Altri studi a Tyler
- Cancro del polmone non a piccole cellule20 studi
- Colite ulcerosa14 studi
- Cancro colorettale8 studi
- Insufficienza cardiaca8 studi
- Cancro (tutti i tipi)7 studi
- Cancro ovarico7 studi
- Cancro dell'endometrio6 studi
- Carcinoma a cellule squamose della testa e del collo6 studi
- Cancro al seno6 studi
- Cancro metastatico5 studi
- Malattia infiammatoria intestinale5 studi
- Leucemia linfatica cronica5 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.